IntelGenx Technologies Corp (IGXT)

[BioSpecialist]

Break out is comingggggggggggggg

GLTA


IGXT.OB

Market Cap : 18 Mio$
Price : 0,56 $

Shares Out : 33 M

http://www.intelgenx.com/_assets/pdf/Rodman-Renshaw-Sept-2009.pdf

Filed NDA with U.S. Food and Drug Administration (FDA) - on April 3, 2009 the Company and Cary Pharmaceuticals filed a New Drug Application (NDA) under CFR 21 paragraph 505(b)(2) for the CPI-300 antidepressant. CPI-300 is a new strength of a leading antidepressant that will provide a more convenient dosing option to patients with major depressive disorder ("MDD").

The NDA has been formally accepted by the FDA for standard review. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, IntelGenx expects the FDA will complete its review or otherwise respond to the NDA by February 6, 2010.